- $1.92bn
- $1.57bn
- $125.58m
Biopharma firm Xencor's Q2 revenue beats on royalty revenue, milestone payments
Brief: Xencor Q2 EPS USD -0.29
Brief: Xencor To Receive $105 Million From Alexion To Resolve Ultomiris® U.S. Royalty Matter
Xencor Q1 revenue falls sharply and misses estimates
Brief: Xencor Q1 EPS USD -1.71
Brief: Xencor Files For Mixed Shelf
Xencor Q4 revenue misses expectations, net loss narrows
Brief: Xencor Q4 EPS USD -0.09
Brief: Xencor Expects To Have Sufficient Cash Resources To Fund Research And Development Programs And Operations Through 2028
Antibody developer Xencor misses Q3 revenue estimates, net loss narrows
Brief: Xencor Q3 EPS USD -0.08
Xencor Inc reports results for the quarter ended June 30 - Earnings Summary
Xencor reports smaller-than-expected Q2 loss
Xencor Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Xencor Q1 EPS USD -0.66 Vs. IBES Estimate USD -0.6
Brief: Xencor Appoints Todd Simpson To Board Of Directors
Xencor Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Xencor Q4 Net Income USD -46.199 Million
Xencor Inc reports results for the quarter ended in January 1 - Earnings Summary